Immunosuppresseurs dans la prévention de la réaction du greffon contre l’hôte : rapport de la SFGM-TC

Belaiche, Stéphanie; Yafour, Nabil; Balcaen, Sandie; Béguin, Yves; Borel, Cécile; Bruno, Bénédicte; Godin, Sandrine; Labussière‐Wallet, Hélène; Sanhamut, N.; Charbonnier, A; Berranger, Eva de; Konopacki-Potet, J.; Turlure, Pascal; Yakoub-Agha, Ibrahim

doi:10.1016/j.patbio.2014.05.010

Cited by 8 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GVHD prophylaxis was conducted according to the SFGM-TC guidelines [25]. Of note, 16 (70%) patients had received antithymoglobulin within the conditioning regimen.…”

Section: Methodsmentioning

confidence: 99%

Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study

Alsuliman

Kitel

Duléry

et al. 2018

Bone Marrow Transplant

View full text Add to dashboard Cite

Cytomegalovirus is one of the main contributing factors to high mortality rates in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). The main factors of treatment failure are both drug resistance and intolerance. In some cases, Cytotect®CP CMV-hyperimmune globulin is used as salvage therapy. This study aims to investigate the safety and efficacy of Cytotect®CP as a salvage therapy in patients with CMV infection after allo-HCT. Twenty-three consecutive patients received Cytotect®CP for CMV infection after prior CMV therapy. At the time of Cytotect®CP introduction, 17 patients (74%) had developed acute GVHD and 15 patients (64%) were receiving steroid treatment; Cytotect®CP was used as monotherapy (n = 7) and in combination (n = 16). Overall, response was observed in 18 patients (78%) with a median time of 15 days (range: 3-51). Of the 18 responders, 4 experienced CMV reactivation, while 5 responders died within 100 days of beginning treatment. Of these 5 deaths, 4 were due to causes unrelated to CMV. Estimated 100-day OS from the introduction of Cytotect®CP was 69.6%. No statistically significant difference was observed in 100-day OS between responders and non-responders (73.7% vs 50.0%, p = 0.258). Cytotect®CP as salvage therapy is effective and well-tolerated. Given its safety profile, early treatment use should be considered.

show abstract

“…GVHD prophylaxis was conducted according to the SFGM-TC guidelines [25]. Of note, 16 (70%) patients had received antithymoglobulin within the conditioning regimen.…”

Section: Methodsmentioning

confidence: 99%